dr reddys labs ppt

WELCOME

05/03/2023Manash Pratim Kalita,Roll No-198,Section-M4

Dr Reddy’s LaboratoriesThe Home-grown Pharmaceutical Giant

Company Based Research Presentation

MANASH PRATIM KALITAROLL NO-198SECTION-M4

Introduction

Dr.Reddy’s laboratories is a premier and major Indian pharmaceutical company headquartered in hyderabad

Founded by Kallam Anji Reddy in 1984 Over 190 medications, 60 active pharmaceutical ingredients(api) for drug

manufacture, diagnostic kits and critical care units To bring new molecules into the country at a price the common man can

afford Global workforce-20000+ Commercial presence-26 countries


Group Companies

Dr. Reddy's laboratories Australia pvt ltd, a wholly owned subsidiary of dr. Reddy's laboratories ltd

In china joint venture with Rotam group Dr. Reddy's operates in Germany through its subsidiary Betapharm Dr. Reddy’s laboratories ltd. decided to enter the market directly through a

joint venture with Venturepharm Dr. Reddy’s laboratories UK ltd was created with the acquisition of BMS

laboratories and its subsidiary meridian healthcare


Goal Good health Commitment That’s why the company believes in “Good health cant wait” Principles Empathy and Dynamism Purpose We accelerate access to affordable and innovative medicines because good

health cant wait


Hierarchy and OrganizationalStructure

CHAIRMAN

COO GLOBAL HR HEAD EVP CFO

CO-CHAIRMAN CUM CEO

Whole time directors Satish Reddy G V PrasadIndependent and non-whole time directors Dr.Omkar Goswami Anupam Puri Kalpana Morparia Dr. Bruce LA Carter


Products and Services

GENERICS- Omez (Omeprazole), Nise (Nimesulide),Ketorol (Ketorolac Thromethamine), Stamlo (Amlodipine Besylate), Razo (Rabeprazole)

OVER THE COUNTER- Cetrine, Nise gel, Ibuclin and Novigan.US nicotine replacement therapy transdermal patch named Habitrol.

API(ACTIVE PHARMACEUTICAL INGREDIENTS)- caters to leading innovator and generic companies across the US, Europe, Latin America, Japan, Korea and other emerging markets such as steroids, peptides, complex long chain synthesis and oncology

BIOLOGICS- Biologics – large molecule protein therapies – for an effective treatment that may have fewer side effects.

DIFFERENTIATED FORMULATIONS- Custom Pharma Services (CPS)


Major Competitors of the Company

Sun Pharma Lupin Aurobindo Pharma Cipla Cadila Ranbaxy Labs Divis labs

International Competitors Abbot Laboratories Abeona Therapeutics


NAMESALES

TURNOVERMARKET SHARE

IN %Sun Pharma 7,614.46 8.137796832Lupin 11,239.80 12.01230407Dr Reddys Labs 10,207.70 10.90926851Aurobindo Pharm 9,166.18 9.796165527Cipla 12,034.06 12.86115303Cadila Health 7,035.30 7.518831545Ranbaxy Labs 6,864.94 7.336762815Divis Labs 3,721.33 3.977094565Piramal Enter 3,516.53 3.758218796GlaxoSmithKline 2,826.21 3.020453556Torrent Pharma 5,429.00 5.802131602Glenmark 6,113.50 6.533676837Alkem Lab 3,924.69 4.194431364Biocon 2,323.60 2.483299501Ajanta Pharma 1,551.76 1.658411445TOTAL 93,569.06 100

8.137796832

12.01230407

10.90926851

9.796165527

12.861153037.518831

545

7.336762815

3.977094565

3.758218796

3.020453556

5.802131602

6.533676837

4.194431364 2.483299501 1.658411445

MARKET SHARE IN %

Sun Pharma Lupin Dr Reddys Labs Aurobindo PharmCipla Cadila Health Ranbaxy Labs Divis LabsPiramal Enter GlaxoSmithKline Torrent Pharma GlenmarkAlkem Lab Biocon Ajanta Pharma

Market Share


OwnershipPARTICULARS % OF SHARESPromoter(individual and companies) 26.37Indian financial institutions 2.83Banks 0.15Mutual funds 2.76FIIs 35.41NRIs 1.25Foreign Companies 2.98Indian Public 11.40


Strength1.Low cost chemotherapy

medicine2.Proprietary chiral and biocatalysis know-how

3.Betapharma acquisition gives access to European markets

Weakness1.Government regulations and

national drug policy2.Huge investment

3.Highly unpredictable sector

Opportunities1.Oncology market entry

2.Partnership in bio-similar markets

3.Cost effective methodologies in emerging markets

Threats1.Preliminary investment very high

2.Patents 3.Foreign giant entry


Financial Analysis

2011 2012 2013 2014 2015 2016 20170

0.5

1

1.5

2

2.5

11111

DEBT EQUITY RATIO


CSR Activities

School-Community Partnership in Education Chindu Pudami Neighborhood Schools KARV – Kallam Anji Reddy Vidyalaya KARV-JC – Kallam Anji Reddy Vocational Junior College Youth Women Household


CSR Expenditure

2016---3.04% 2014-15---1.74% 2013-14---1.03% 2012-13---1.33% CSR provisions in Companies Act,2013 every company, private limited or public limited, which either has a net worth of Rs 500 crore or a

turnover of Rs 1,000 crore or net profit of Rs 5 crore, needs to spend at least 2% of its average net profit for the immediately preceding three financial years on corporate social responsibility activities


Employee Benefits


Economic Analysis

High economies of scale Low cost products so tough entry for players Extensive R&D hence no threats from patent expiration Alliances, joint ventures or acquisition Easing of norms under “Make in India” programme


Conclusion

Made healthcare more affordable Giant Indian player in US, Russia and CIS countries FDA regulations getting tougher Currently focus is not only on foreign countries but also in India NYSE listed company


THANK YOU


dr reddys labs ppt

Documents